[en] Even if type 2 diabetes is a complex disease combining hyperglycaemia and various other metabolic abnormalities. Reduction of chronic hyperglycemia, assessed by glycated haemoglobin (HbA1c), allows the prevention or the delay of vascular complications. Evidence-based medicine already provided numerous data regarding the risk of microangiopathy, especially retinopathy and nephropathy but also neuropathy. The evidence is less obvious as far as macroangiopathy, especially coronary artery disease, is concerned. This observation should encourage a global approach of the type 2 diabetic patient, taking into account all vascular risk factors. It also provides further arguments in favour of alternative therapeutic modalities, such as the use of hypoglycaemic agents that improve postprandial hyperglycaemia and/or insulin resistance. This latter approach appears to be promising in view of the favourable results with metformin in the United Kingdom Prospective Diabetes Study. It should be confirmed in large prospective ongoing clinical trials with new insulin sensitizers like thiazolidinediones.
Disciplines :
Endocrinologie, métabolisme & nutrition
Auteur, co-auteur :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Paquot, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Langue du document :
Français
Titre :
Role specifique du controle glycemique dans la prevention de l'angiopathie du patient diabetique de type 2.
Titre traduit :
[en] Blood glucose control and prevention of microangiopathy and macroangiopathy in type 2 diabetes
Date de publication/diffusion :
2003
Titre du périodique :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Maison d'édition :
Université de Liège. Revue Médicale de Liège, Liège, Belgique
Massi-Benedetti M (Ed). - The cost of diabetes type II in Europe. The CODE-2 study. Diabetologia, 2002, 45 (Suppl 1), S1-S28.
WHO Study Group on Prevention of Diabetes Mellitus. - Prevention of diabetes mellitus. WHO Technical report series, 844, World Health Organisation, Geneva, 1994.
Gandjour A, Kleinschmit F, Lauterbach KW and the INTERCARE International Investigators. - European comparison of costs and quality in the prevention of secondary complications in Type 2 diabetes mellitus (2000-2001). Diabetic Med, 2002, 19, 594-601.
Klein R. - Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care, 1995, 18, 258-268.
Groeneveld Y, Petri H, Hermans J, Springer MP. - Relationship between blood glucose level and mortality in type 2 diabetes mellitus: a systematic review. Diabetic Med, 1999, 16, 2-13.
Pirart J. - Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (part 1). Diabetes Care, 1978, 1, 168-188.
Gaster B, Hirsch IB. - The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med, 1998, 158, 134-140.
Diabetes Control Complications Trial Research Group. - The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993, 329, 977-986.
UK Prospective Diabetes Study Group. - Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
Stratton IM, Adler AI, Neil AW, et al on behalf of the Prospective Diabetes Study Group. - Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ, 2000, 321, 405-412.
Sheetz MJ, King GL. - Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 2002, 288, 2579-2588.
Avignon A, Monnier L. - Rôle spécifique des pics glycémiques postprandiaux sur l'HbA1c et l'angiopathie. Diabetes Metab, 2000, 26 (Suppl 2), 12-15.
Scheen AJ, Paquot N, Jandrain B, Lefèbvre PJ. - L'hyperglycémie post-prandiale. I. Physiopathologie, conséquences cliniques et approches diététiques. Rev Med Liège, 2002, 57, 138-141.
Scheen AJ. - Le syndrome X, à la croisée des maladies métaboliques et cardio-vasculaires. Rev Med Liège, 1998, 53, 29-32.
Beckman JA, Creager MA, Libby P. - Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570-2581.
Scheen AJ, Paquot N. - Le diabète de type 2: approches diagnostiques, objectifs glycémiques et stratégies thérapeutiques. Rev Med Liège, 1999, 54, 659-666.
Mooradian AD. - Cardiovascular disease in type 2 diabetes mellitus. Current management guidelines. Arch Intern Med, 2003, 163, 33-40.
Scheen AJ, Estrella F. - L'étude Steno-2: plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2. Rev Med Liège, 2003, 58, 109-111.
Paquot N, Scheen AJ. - Prévention cardio-vasculaire du patient diabétique de type 2. Rev Med Liège, 2003, 58, 271-274.
Scheen AJ, Bruwier G, Schmitt H, au nom des membres de l'étude clinique DREAM. - Optimalisation de la prise en charge du patient diabétique de type 2: résultats de l'étude "DREAM" en médecine générale. Rev Med Liège, 2003, 58, 139-146.
Ohkubo Y, Kishihawa H, Araki E, et al. - Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract, 1995, 28, 103-117.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. - Longterm results of the Kumamoto Study on optimal diabetes control in type 2 patients. Diabetes Care, 2000, 23 (Suppl 2), B21-B29.
Gaede P, Vedel P, Parving HH, et al. - Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet, 1999, 353, 617-622.
Gaede P, Vedel P, Larsen N, et al. - Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-393.
The DECODE study group. - European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999, 354, 617-621.
UK Prospective Diabetes Study (UKPDS) Group. - Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854-865.
Campbell IA. - Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus? Drugs, 2000, 60, 1017-1028.
Wagstaff AJ, Goa KL. - Rosiglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs, 2002, 62, 1805-1837.
ANAES. - Suivi du patient diabétique de type 2 à l'exclusion des complications. Diabetes Metab, 1999, 25 (suppl 2), 9-13.
American Diabetes Association. - Standards of medical care for patients with diabetes mellitus. Diabetes Care, 2003, 26 (Suppl 1), S33-S50.
European Study Group. - A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group. Diabetic Med, 1999, 16, 716-730.
